Compare PLAG & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLAG | SNTI |
|---|---|---|
| Founded | 1986 | 2016 |
| Country | United States | United States |
| Employees | 6 | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.6M | 24.5M |
| IPO Year | 2007 | 2021 |
| Metric | PLAG | SNTI |
|---|---|---|
| Price | $1.40 | $0.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 84.7K | ★ 93.5K |
| Earning Date | 05-14-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 32.56 | ★ 77.31 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,040,616.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.47 | $0.77 |
| 52 Week High | $4.49 | $5.10 |
| Indicator | PLAG | SNTI |
|---|---|---|
| Relative Strength Index (RSI) | 39.44 | 55.24 |
| Support Level | $1.29 | $0.78 |
| Resistance Level | $2.05 | $1.02 |
| Average True Range (ATR) | 0.16 | 0.05 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 10.96 | 96.88 |
Planet Green Holdings Corp is a diversified technology and consumer products company with a presence in North America and China engaged in Chemical Products, Tea Products, and Online Advertising Services. The company operates in three segments namely to grow, produce, and distribute Cyan brick tea, black tea, and green tea in China; to research, develop, manufacture, and sell chemical products including formaldehyde, urea formaldehyde adhesive, methylal, ethanol fuel, fuel additives and clean fuel in China; and to develop and operate a demand-side platform which empowers buyers of advertising to manage and optimize their digital advertising across different real-time bidding networks in North America and China.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.